rawfin.tv
Brii Biosciences Acquires VBI's BRII-179 IP Rights for Clinical Expansion
Top StoriesstocksAI Generated

Brii Biosciences Acquires VBI's BRII-179 IP Rights for Clinical Expansion

By rawfin.tv Markets Desk||1 min read|AI-assisted · Methodology

Brii Biosciences announced an agreement to acquire intellectual property rights for BRII-179 (VBI-2601) from VBI Vaccines. The acquisition aims to facilitate technology transfer and expand clinical and commercial supplies of the compound, strengthening Brii's pipeline.

BiotechM&APharmaceuticalsIntellectual PropertyDrug Development

Related Articles

Adidas Surges 37% to Record Q3 Profit, Lifts Full-Year Targets

Adidas Surges 37% to Record Q3 Profit, Lifts Full-Year Targets

stocks
EQT to Acquire Cleanaway Waste for $6.5 Billion

EQT to Acquire Cleanaway Waste for $6.5 Billion

stocks
S&P 500 Breaches Key Support as AI Sell-Off Pressures Tech Sector

S&P 500 Breaches Key Support as AI Sell-Off Pressures Tech Sector

stocks
US Chip Stocks Plunge 16% in Longest Losing Streak Since 2008

US Chip Stocks Plunge 16% in Longest Losing Streak Since 2008

stocks